12th International Society for Study of Xenobiotics (ISSX 2019)

Event Date: July 28 - August 1, 2019

Event Location: Oregon Convention Center, 777 NE Martin Luther King, Jr. Blvd, Portland, OR 97232

Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit

Diapharma is planning to attend the 12th International Society for Study of Xenobiotics (ISSX 2019) Meeting this year. Please click here to schedule a meeting with us or email us directly.

About ISSX 2019Xenobiotics measurement assay test kit

ISSX 2019 is a meeting for the entire society that offers a broad ranging program to serve the interests of all its scientific and geographical constituencies.

ISSX 2019 Topics Include

  • Advances in the Role of Transporters in Drug Development
  • Predicting and Verifying Tissue Drug Concentrations Using a Proteomics and PET Imaging Approach
  • Advancing Predictions of Tissue and Intracellular Drug Concentrations Using in vitro and PBPK Modeling Approac hes
  • Influence of Transporter Polymorphisms on Drug Disposition and Response
  • Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk?
  • Transporter DDIs
  • Non-P450 Enzymes in ADMET for Drug Discovery and Development
  • Overview of Non-P450-mediated Metabolism in Drug Development
  • Role of Glucuronidation in Drug Metabolism and Toxicity
  • Enzymology and Clinical Importance of Reductases and Hydrolases
  • Significance of Hydrolases and Aldehyde Oxidase in Drug Toxicity
  • State of the Art PKPD and QSP Modeling
  • Introduction to QSP
  • How to Build a QSP Model in Less than One Hour
  • Application of QSP in Drug Discovery
  • Therapeutic Area Case Study: QSP in Immuno-oncology
  • Therapeutic Area Case Study: QSP in Inflammatory Disease
  • Idiosyncratic Drug-induced Liver Injury
  • The Role of Inflammatory Mediators in Idiosyncratic Drug-induced Liver Injury
  • Clinical Aspects of Hepatocellular and Cholestatic Drug-induced Liver Injury
  • Understanding Genetically-inherited Susceptibility Factors, Including HLA Genotype
  • Use of Pharmacogenomics and Other Patient-specific Factors to Individualize Drug Dosing and Treatment
  • Warfarin: A Paradigm for Individualized Dosing
  • Relevance of Transporter and Metabolic SNPs to Pediatric Treatment
  • CPIC Guidelines and Implementation to Date
  • Personalised Treatment of Cancer
  • State of the Art for Organs on Chips
  • Kidney Organoids for Disease Modeling and High Throughput Screening
  • Real-time Toxicity Assessment on Perfused 3D Epithelial Tubes
  • Tissues on Chips- A Novel Tool for Toxicity and Efficacy Testing on Human Tissue
  • Biofabrication of Liver Constructs for Drug Toxicity Studies
  • Quantitative Pharmacokinetic and Pharmacology Methods and Strategies in the Discovery and Development of Biotherapeutics
  • Development and Application of a PBPK Model for Large Molecules
  • PBPK and PKPD Modeling to Investigate Engineered Antibodies
  • PBPK Models for Predicting Human PK for Monoclonal Antibodies and Other Large Molecule Modalities
  • Systems PK/PD Model Informed Discovery and Development of Cancer Immunotherapy
  • Microbiome-Environment-Drug Interactions: Emerging Tools and Applications
  • Impact of Intestinal Flora on Host Metabolism of Drug, Sugar and Lipid
  • Activity-based Profiling of the Microbiome Response to Chemical Exposures
  • Impact of the Human Gut Microbiome on Drug Disposition
  • Developmental Reprogramming of the Gut Microbiota by Environmental Toxicants
  • Disease Effect on Transporter Regulation and Function
  • Proteomics Based Studies of Disease Effects on the Brain Barrier Transporters
  • Transporters in Polycystic Kidney Disease
  • Liver Transporter Activity in Patients with Renal Disease
  • Advances in the Study of Drug Metabolism
  • Predicting Routes, Sites, and Products of Metabolism
  • Substrate Recognition by Cytochrome P450s
  • Application of in silico DMPK in Drug Discovery and Development
  • Biosynthesis of Drug Candidates and Metabolites
  • Transporter Polymorphisms Drive Inter-ethnic Differences in Drug Response
  • Impact of Racial/Ethnic Differences in Drug Response: Regulatory Perspectives
  • State-of-the-Art Approaches in Drug Metabolizing Enzymes and Transporters (DMET) Biomarker Research: Path from Discovery to Validation
  • Biomarkers for in vivo Assessment of Transporter Function
  • Mechanistic Models for Coproporphyrin I and Creatinine as Endogenous Biomarkers for Transporter Drug-Drug Interactions
  • Knockout Mice, Transcriptomics and Metabolomics Approach for Discovery of Endogenous Biomarkers for Renal Drug Transporters
  • Integrated Quantitative Proteomics and Metabolomics Approach for Discovery and Validation of UGT2B17 Biomarker to Predict Drug Metabolism
  • Biotransformation Mechanisms and Pathways
  • Role of Albumin in Drug Disposition Revisited
  • Albumin-mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates
  • Effects of Albumin on Prediction of Liver Kpuu and Human Hepatic Clearance for Enzyme- and Transporter-Mediated Mechanisms
  • Impact of Albumin and Plasma on the Renal Uptake of OAT1 Substrates
  • Ontogeny of Enzymes and Transporters and their Implications in Pediatric PBPK Modeling to Inform Pediatric Dosing
  • Ontogeny of Human Membrane Transporters: from Data to Application
  • Pediatric PBPK: Dealing with Uncertain Parameters and Deciding on Success Criteria for Predictability
  • ‘Virtual Children’ to Inform Exposure-Controlled Dosing of Drugs in Children
  • Building, Verifying and Validating Pediatric PBPK Models: Vulnerabilities and Knowledge Deficits
  • ADME Issues Encountered and Addressed in Drug Discovery and Development
  • Management of MIST in a Case of Multiple Metabolic Species Differences

About ISSX

As the foremost organization representing the interests of researchers and educators in the field, the Society is engaged in multiple activities to support, promote, and advance the profession on a global scale.

ISSX Mission

ISSX advances research and education on the interplay of living systems with medicines and chemicals for the benefit of society worldwide.

ISSX Meetings

ISSX meetings bring together a network of academic and industry research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics.

Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit

ISSX | Twitter | Facebook | LinkedIn | Oregon Convention Center